243 related articles for article (PubMed ID: 15608563)
1. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
Yin OQ; Tomlinson B; Waye MM; Chow AH; Chow MS
Pharmacogenetics; 2004 Dec; 14(12):841-50. PubMed ID: 15608563
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
3. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
4. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
[TBL] [Abstract][Full Text] [Related]
5. Artemisinin induces omeprazole metabolism in human beings.
Svensson US; Ashton M; Trinh NH; Bertilsson L; Dinh XH; Nguyen VH; Nguyen TN; Nguyen DS; Lykkesfeldt J; Le DC
Clin Pharmacol Ther; 1998 Aug; 64(2):160-7. PubMed ID: 9728896
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
[TBL] [Abstract][Full Text] [Related]
7. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.
Böttiger Y
Eur J Clin Pharmacol; 2006 Aug; 62(8):621-5. PubMed ID: 16791583
[TBL] [Abstract][Full Text] [Related]
8. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
[TBL] [Abstract][Full Text] [Related]
10. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
11. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Fan L; Wang G; Wang LS; Chen Y; Zhang W; Huang YF; Huang RX; Hu DL; Wang D; Zhou HH
Acta Pharmacol Sin; 2007 Oct; 28(10):1685-92. PubMed ID: 17883958
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
[TBL] [Abstract][Full Text] [Related]
13. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
[TBL] [Abstract][Full Text] [Related]
14. Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status.
Ieiri I; Kimura M; Irie S; Urae A; Otsubo K; Ishizaki T
Pharmacogenet Genomics; 2005 Dec; 15(12):851-9. PubMed ID: 16272957
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Rost KL; Roots I
Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
18. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
20. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]